AngioDynamics Inc operates as a medical device company, specializing in the design, development, manufacturing, and marketing of medical, surgical, and diagnostic devices used in minimally invasive procedures. The company's business model focuses on providing innovative solutions to healthcare professionals for the treatment of vascular diseases and conditions. AngioDynamics offers a wide range of products, including ablation systems, thrombus management devices, venous access products, and peripheral vascular devices. By delivering high-quality and reliable medical devices, AngioDynamics aims to improve patient outcomes and provide value to healthcare providers.

AngioDynamics Inc is primarily active in the medical device industry.

The main competitors of AngioDynamics Inc in the market include Medtronic Inc, Boston Scientific Corporation, and Johnson & Johnson.

AngioDynamics Inc. is a leading medical technology company specializing in the development and manufacture of innovative medical devices used in minimally invasive procedures. The company was founded in 1988 and is headquartered in Latham, New York. AngioDynamics Inc. has a rich history of delivering cutting-edge solutions in areas such as vascular access, peripheral vascular disease, and oncology. With a commitment to improving patient outcomes, AngioDynamics Inc. has established itself as a trusted provider of advanced medical devices to healthcare professionals worldwide. The company's dedication to research, development, and clinical collaboration ensures continued success in the field of minimally invasive interventions.

AngioDynamics Inc has achieved several significant milestones throughout its existence. One notable accomplishment includes the development and commercialization of innovative medical devices for the treatment of peripheral vascular disease and cancer. The company has also expanded its global presence by successfully introducing its products in various international markets. Furthermore, AngioDynamics Inc has received numerous accolades and recognition for its breakthrough technologies, including the FDA approval of its groundbreaking radiofrequency ablation system. With a steadfast commitment to improving patient outcomes, AngioDynamics Inc continues to make strides in the field of medical technology and remains at the forefront of innovation.

AngioDynamics Inc is primarily present in the United States.

AngioDynamics Inc represents values of innovation, patient focus, and commitment to improving medical treatments. The company's corporate philosophy revolves around developing and delivering breakthrough medical technologies that enhance patient care and improve the quality of life. AngioDynamics is dedicated to providing innovative solutions for minimally invasive, image-guided medical procedures, with a focus on delivering superior outcomes for patients. With a strong emphasis on research and development, AngioDynamics continuously strives to advance medical technologies, ensuring patient safety, and revolutionizing the field of medical interventions.

Analysts currently set an average price target of 19.72 USD for the AngioDynamics stock (median: 18.36 USD), implying +46.0 % versus the latest price. The consensus is based on 10 analyst ratings.

AngioDynamics Analyst Price Targets 2026

10 analysts currently rate the AngioDynamics stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AngioDynamics to generate revenue of 314.02 M USD and earnings per share of -0.21 USD.

AngioDynamics Analyst Price Targets 2026

Converted at the current exchange rate, the AngioDynamics share trades at 11.82 EUR (13.51 USD).

The AngioDynamics share (ANGO) is listed on 2 stock exchanges, including: NASDAQ (ANGO), Frankfurt (UG2.F).

AngioDynamics Inc. is a leading company in the field of minimally invasive medicine and offers innovative medical technology solutions for vascular diseases, cancer treatment, and interventional radiology. The company operates globally and distributes its products in over 90 countries. The company operates in three main business areas: Vascular Access, Peripheral Vascular, and Oncology. The Vascular Access area includes products such as port systems, catheters, and accessories used to create long-term vascular access for patients requiring repeated blood draws or infusions. The Peripheral Vascular area includes products such as atherectomy systems, thrombectomy systems, and stent systems used for the treatment of peripheral vascular diseases such as atherosclerosis and thrombosis. Oncology offers a wide range of products and systems for cancer treatment, including catheters and port systems. Another important area of AngioDynamics is interventional radiology. The company offers innovative instruments and systems for the diagnosis and treatment of diseases such as liver tumors and prostate enlargement. Products in this area include microwave-assisted tumor ablation systems, needles, catheters, and accessories. AngioDynamics is also a key player in the field of medical imaging. The company provides systems for navigation and visualization of catheters and instruments used in minimally invasive procedures. These products enable physicians to perform precise and safe procedures and offer patients faster recovery. The business model of AngioDynamics is based on the development and marketing of innovative medical solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company invests in research and development to develop new products and technologies that meet the needs of physicians and patients. Additionally, the company collaborates closely with hospitals and medical facilities to ensure rapid adoption and dissemination of its products. AngioDynamics has a strong and diverse product line that enables the company to serve various markets and customers. The company offers high-quality products and solutions that are valued in medical practice worldwide. With its leadership role in research and development of minimally invasive medicine, AngioDynamics is well positioned to continue growing and maintaining its position as a leading company in the industry. Overall, AngioDynamics' business model is focused on providing innovative medical products and solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company operates in multiple business areas and has a strong presence in the global market. With its extensive product line, leadership role in research and development, and close collaboration with hospitals and medical facilities, AngioDynamics is well positioned to maintain its leading role in the industry in the future.

The expected revenue of AngioDynamics is 314.02 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of AngioDynamics is -8.38 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of AngioDynamics is currently -65.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AngioDynamics stock.

The price-to-sales ratio (P/S) of AngioDynamics is currently 1.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AngioDynamics stock.

The Eulerpool Quality Score for AngioDynamics is 1/10.

The ISIN of AngioDynamics is US03475V1017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of AngioDynamics is A0B9A5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of AngioDynamics is ANGO. The ticker symbol is used to trade AngioDynamics shares on the stock exchange.

AngioDynamics paid dividends every year for the past 0 years.

AngioDynamics is assigned to the 'Health' sector.

The dividends of AngioDynamics are distributed in USD.